MOCHA study of blood and biopsy features in stomach tumors
Part of Cancer, Digestive system clinical trials.
This study looks at the “molecular” features (biologic characteristics) of gastroesophageal cancer from tissue samples. It may help doctors better understand which cancers are best matched to treatment plans and future therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have gastroesophageal (stomach/food pipe) cancer that fits one of two situations: early/localized for surgery, or advanced for palliative treatment.
- For the advanced group, you must be able to safely get a CT- or ultrasound-guided needle biopsy before starting systemic treatment.
- Your cancer needs to have at least one other measurable spot (or, in some locally advanced non-metastatic cases, you may be exempt).
- You should be well enough for procedures and treatment (performance status 0–2) and expected to live more than 90 days.
- For the advanced group, your first treatment plan must include platinum-based chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This trial tests if using specific biomarkers (like HER2 and PD-L1) can help choose the best treatment to potentially avoid surgery. It aims to preserve the stomach or esophagus while effectively treating the cancer.
This study looks at how the immune system behaves in stomach or lower esophagus cancer before standard (planned) surgery. It may help researchers understand which immune features relate to outcomes and treatment response.
This trial looks at tiny pieces of DNA found outside cells in stomach tissue to better understand how gastric (stomach) cancer starts and progresses. It may help future patients by improving how doctors study stomach cancer from biopsy and surgical samples.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This trial is testing whether using a blood test to find tiny amounts of cancer DNA after initial treatment can guide decisions about further therapy for people with stomach cancer. The goal is to personalize follow-up treatment to reduce the chance of cancer returning.
Hear when a new Esophagogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.